Searching for Early Warning Signs of ALS in Adults
Tests spinal fluid samples from adults with ALS to find early markers of the disease.
Plain-language title generated from the registry record
Registry title: Identification of Early Markers for ALS
Key facts
- Where
- Tours, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07213440, who can take part
Where in France
- CHU ToursTours, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut National de la Santé Et de la Recherche Médicale, France
- Trial code
- NCT07213440
- Record updated
- 7 July 2026
- Original description
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies.Read full original descriptionShow less
Identification of Early Markers for ALS
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies.
In this project, the investigators will develop a clinical molecular fingerprint of PGMC that will provide insight into the molecular pathogenesis of ALS and allow earlier diagnosis.
Inclusion: FIRST GROUP: Premotor gene mutation carriers (PGMC):; 18-90 years of age; Provision of a written informed consent; Affiliation with a social security scheme or beneficiary of such a scheme; Diagnosed by a clinically certified laboratory with a disease- causing mutation in a known ALS gene by predictive genetic testing; No symptoms of motor neuron disease explainable otherwise than by mutation in a known ALS gene; SECOND GROUP: Control subjects to premotor gene mutation carriers (CTR):; 18-90 years of age; Provision of a written informed consent; Affiliation with a social security scheme or beneficiary of such a scheme; No known genetic mutation and no known ALS disease in close family; No diagnosed motor-neuron disease; THIRD GROUP: ALS (EALS) / ALS mimics (MIM); 18-90 years of age; provision of a written informed consent; affiliation with a social security scheme or beneficiary of such a scheme; Patients with pure motor symptom or early ALS (EALS) or ALS mimics (MIM); EALS are patients with pure motor symptom / early motor symptoms of ALS, including those, where the diagnosis of ALS can already be made. These may be patients who meet the following criteria:; According to El Escorial criteria : patients who can be classified as possible ALS or those who show upper motor neuron (UMN) signs only or lower motor neuron (LMN) signs only, so that classification as possible ALS is also not possible. Symptoms should not persist for more than 12 months; According to Gold Coast criteria: Patients who do not fulfill the criterion of temporal progression or patients who only show UMN signs or only LMN signs in one region and thus do not fulfill the diagnostic criteria of ALS.
Exclusion: Inability to express consent to the study; Persons subject to a judicial safeguard measure, under guardianship or curatorship; Linguistic incapacity or psychic refusal to read the information; Pregnant women; Foreseen inability to attend scheduled visits; Persons refusing to take one of the following samples: Acquisition of blood samples, Acquisition of tear fluid samples, Acquisition of urine sample.